Analysis of Open Innovation Efforts alongside the biopharmaceutical industry’s value chain in Iran

سیادتی, سیدهادی; gh, سید سپهر; منطقی, منوچهر

doi:10.30495/jomm.2022.66447.1924

Manuscript ID : JOMM-2203-1924 (R1) Visit : 94 Page: 41 - 64

10.30495/jomm.2022.66447.1924

Article Type: Original Research

Analysis of Open Innovation Efforts alongside the biopharmaceutical industry’s value chain in Iran

Subject Areas : Jounal of Marketing Management

سیدهادی سیادتی ¹ (PhD Student in Technology Management, Science and Research Branch, Islamic Azad University, Tehran, Iran)
سید سپهر gh ² (Professor, Department of Information Technology Management, Tarbiat Modares University, Tehran, Iran)
منوچهر منطقی ³ (Associate Professor, Department of Technology Management, Malek Ashtar University of Technology, Tehran, Iran)

Received: 2022-03-05 Accepted : 2022-04-04 Published : 2022-09-23

Keywords: open innovation, Multi-Case Study, Value Chain, Biopharmaceuticals,

Abstract :

Introduction: The market of biopharmaceuticals in the world is growing rapidly and in our country the share of these drugs is increasing. Research, development, production and sale of these drugs have high risk and cost and require a long time. Hence, global companies are turning to technological and innovative collaborations. In Iran, however, the issue of cooperation between biopharmaceutical companies has not been addressed. Research Method: In order to identify the ways in which the actors of this industry cooperate along the value chain, the present study has tried to draw the actors in each of the links of the chain by studying two cases in Sinagen and Ronak Daroo companies. The present study is an applied type and interpretive paradigm in a way that using a multi-case study strategy, attempts have been made to identify ways of technological cooperation between different actors along the value chain. The interviews with each of the interviewees consisted of 13 main questions and were in the form of a semi-structured interview. Findings: The results of this study show that although good cooperation has been formed between the actors of this industry for the production of medicine. But these collaborations have been more about developing the market or producing biosimilars than on developing technology and upgrading research capabilities and developing new drugs. Also, despite the formation of few technological collaborations between companies in the industry, the lack of specialized companies such as clinical trial companies and small biotechnology companies, legal shortcomings such as the weakness of the commercial law for mergers and acquisitions and the weakness of use Export development tools are among the most important problems facing the promotion of technological cooperation between companies in this industry. Conclusion: Iranian biopharmaceutical companies generally acquire their production knowledge through reverse engineering and for the production of biosimilars and perform the distribution and after-sales service themselves.

References:

باقری، ک. و شاوردی، م. (1396). "نوآوری باز، پارادایم نوین آفرینش و تجاری سازی"، انتشارات رسا، تهران.

تسلیمی، م.س.، نقوی، م.ح.، مختارزاده، ن. و بابایی، ع. (1397). "نقش نهادهای واسطه‌ای در ظهور صنعت زیست داروها در ایران"، فصلنامه سیاست علم و فناوری، شماره 39، صص. 29-44.

جعفری، ی.، حیدری، م.، مرتضوی، ن. و همراهی، ر. (1395). "بیوسیمیلارها، فرصتی برای شکست قیمت داروها"، فصلنامه ایمنی زیستی، دوره 9، شماره 1، صص. 21-30.

حمیدی‌مطلق، ر.، عیسایی، م. و بابایی، ع. (1395). "درهم تنیدگی دولت - کارآفرین پیشگام و تحول فناورانه: مورد کاوی رشد سریع فناوری زیست دارو در ایران"، فصلنامه سیاست علم و فناوری، دوره 8، شماره 4، صص. 1-18.

رادفر، ر.، پیله‌وری، ن.، قاضی نوری، س.س. و شاکری، ر. (1394). "مطالعه پیشرانه‌های قابلیت ائتلاف استراتژیک در سطح بنگاه؛ مورد صنعت زیست داروئی"، پژوهش‌های مدیریت عمومی، دوره 8، شماره 27، صص. 45-70.

شاکری، ر. (1394). "ارائه الگوی ارزیابی عملکرد استراتژی‌های تجاری سازی زیست فناوری؛ رویکرد مدل سازی سیستمی"، رساله دکتری، رشته مدیریت تکنولوژی، گرایش مدیریت تحقیق و توسعه، دانشگاه آزاد اسلامی، واحد علوم و تحقیقات تهران.

شریف زاد، ف. و قوچانی خراسانی، م. (1393). "شناسایی انواع شبکه‌های نوآوری و نقش آن‌ها در حوزه‌های فناوری شرکتی تحقیقاتی در صنعت الکترونیک"، فصلنامه مطالعات مدیریت فناوری اطلاعات، دوره 2، شماره 7، صص. 109-142.

طباطبائیان، ح.، طهوری، ح.، تقوا، م. و تقوی فرد، م. (1397). "تحلیل اکوسیستم نوآوری داروهای زیستی ایران"، فصلنامه مدیریت توسعه فناوری، دوره 5، شماره 4. صص. 9-46.

قاضی نوری، س. و شاکری، ر. (1396). "یکپارچه‌سازی سیاست‌های صنعتی، تجاری و فناوری در حوزه داروهای زیستی"، مؤسسه مطالعات و پژوهش‌های بازرگانی، طرح تحقیقاتی.

کارگرشهامت، ب.، تقوا، م.، طباطبائیان، ح. و صالحی، ج. (1395). "الزامات شکل‌گیری شبکه نوآوری؛ تحلیلی از قاعده بنگاه‌داری در بخش دارویی ایران. بهبود مدیریت، دوره 10، شماره 4، صص. 49-94.

گودرزی م. و گودرزی، م. (1393). "بررسی فرآیند تجاری‌سازی زیست داروها: درس‌هایی برای صنعت داروی ایران"، رهیافت، دوره 24، شماره 57، صص. 33-50.

Afshari-Mofrad, M. & Salim, A. (2019). “Iranian firms in biopharmaceutical value chain: where to go now?”, Journal of Science and Technology Policy Management, Vol. 11(1), PP. 49-63.

Behme, S. (2015). “Manufacturing of Pharmaceutical Proteins: From Technology to Economy”, John Wiley and Sons, Hoboken, NJ, PP. 3-9.

Bianchi, M., Alberto, C., Davide, C., Federico, F. & Vittorio, C. (2011). “Organisational modes for Open Innovation in the bio-pharmaceutical industry: An exploratory analysis”, Technovation, Vol. 31(1), PP. 22-33.

Chesbrough, H.W. (2003). “Open innovation: The new imperative for creating and profiting from technology”, Harvard Business Press.

Chiaroni, D., Chiesa, V. & Frattini, F. (2009). “Investigating the adoption of open innovation in the bio‐pharmaceutical industry”, European Journal of Innovation Management, Vol. 12(3), PP. 285-305.

Choi, M., Lee, R. & Wong, J. (2011). “Biopharma R&D in China: making bets pay off”, The Boston Consulting Group, Working paper.

Kale, D. & Steve, L. (2007). “From imitation to innovation: The evolution of R&D capabilities and learning processes in the Indian pharmaceutical industry”, Technology Analysis & Strategic Management, Vol. 19(5), PP. 589-609.

Malerba, F. & Luigi, O. (2002). “Innovation and market structure in the dynamics of the pharmaceutical industry and biotechnology: towards a history‐friendly model”, Industrial and corporate change, Vol. 11(4), PP. 667-703.

Mazzola, E., Manfredi, B. & Giovanni, P. (2016). “Open innovation and firms’ performance: state of the art and empirical evidences from the bio-pharmaceutical industry”, International Journal of Technology Management, Vol. 70(2-3), PP. 109-134.

Mortara, L. & Tim, M. (2011). “How do large multinational companies implement open innovation?”, Technovation, Vol. 31(10-11), PP. 586-597.

Munos, B. (2009). “Lessons from 60 years of pharmaceutical innovation”, Nature reviews Drug discovery, Vol. 8(12), PP. 959-968.

Mytelka, L.K. (2006). “Pathways and policies to (bio) pharmaceutical innovation systems in developing countries”, Industry and Innovation, Vol. 13(4), PP. 415-435.

Perri, A., Vittoria G, S. & Ram, M. (2017). “What are the most promising conduits for foreign knowledge inflows? Innovation networks in the Chinese pharmaceutical industry”, Industrial and Corporate Change, Vol. 26(2), PP. 333-355.

Powell, W.W., Kenneth W, K. & Laurel, S.D. (1996). “Interorganizational collaboration and the locus of innovation: Networks of learning in biotechnology”, Administrative science quarterly, PP. 116-145.

Raja, B.H. & Sambandan, P. (2015). “Open innovation in pharmaceutical industry: a case study of Eli Lilly”, Master of Science Thesis INDEK.

Rikap, C. (2017). “The Differentiated Market-University. Structural differences among university’s commodification processes”, Theory and Method in Higher Education Research, Vol. 3, PP. 179-196.

Rikap, C. (2019). “Asymmetric Power of the Core: Technological Cooperation and Technological Competition in the Transnational Innovation Networks of Big Pharma”, Review of International Political Economy, Vol. 26(5), PP. 987-1021.

Sabatier, V., Vincent, M. & Rousselle, T. (2010). “Orchestrating networks in the biopharmaceutical industry: small hub firms can do it”, Production Planning and Control, Vol. 21(2), PP. 218-228.

Siadati, H. & Afshari-Mofrad, M. (2019). “Policies for promoting open innovation”, Journal of Science and Technology Policy, Vol. 11(2), PP. 379-393.

Wang, X., Zhi-lin, S. & Ling-yu, W. (2009). “Evaluation of biopharmaceutical enterprises based on value chain analysis”, In 2009 International Conference on Management Science and Engineering, PP. 518-527. IEEE.

Yin, R.K. (2017). “Case study research and applications: Design and methods”, Sage publications.

_||_